Brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to post earnings of $1.73 per share for the current quarter, Zacks reports. Seven analysts have provided estimates for Gilead Sciences’ earnings. The highest EPS estimate is $1.89 and the lowest is $1.57. Gilead Sciences reported earnings per share of $1.91 in the same quarter last year, which indicates a negative year over year growth rate of 9.4%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, July 24th.
On average, analysts expect that Gilead Sciences will report full year earnings of $6.89 per share for the current financial year, with EPS estimates ranging from $6.52 to $7.10. For the next fiscal year, analysts forecast that the business will post earnings of $7.11 per share, with EPS estimates ranging from $6.44 to $7.35. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.53 by $0.23. The firm had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. Gilead Sciences’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.48 earnings per share.
Shares of Gilead Sciences stock opened at $65.35 on Thursday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The stock has a market capitalization of $83.31 billion, a P/E ratio of 10.63, a PEG ratio of 0.80 and a beta of 1.10. Gilead Sciences has a fifty-two week low of $60.32 and a fifty-two week high of $79.61.
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.63 dividend. The ex-dividend date is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a yield of 3.86%. Gilead Sciences’s payout ratio is currently 40.98%.
In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $62.61, for a total value of $169,047.00. Following the completion of the transaction, the director now directly owns 57,560 shares in the company, valued at $3,603,831.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,602 shares of company stock valued at $1,863,445. 0.20% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Athena Capital Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth approximately $27,000. Capital Financial Planning LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth approximately $27,000. Creative Financial Designs Inc. ADV boosted its position in shares of Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 165 shares during the period. Claybrook Capital LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth approximately $32,000. Finally, Trustcore Financial Services LLC acquired a new position in shares of Gilead Sciences during the first quarter worth approximately $34,000. Institutional investors and hedge funds own 78.71% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: How analysts view the yield curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.